Bioactive lipids in schizophrenia
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Bioactive lipids, in particular arachidonic acid (AA), are vital for monoaminergic neurotransmission, brain development and synaptic plasticity. Phospholipases A2 (PLA2) are key-enzymes in AA metabolism and are activated during monoaminergic neurotransmission. Reduced membrane AA levels, and an altered activity of PLA2 have been found in peripheral membranes of drug-naïve patients with schizophrenia with some conflicting results in more chronic patient populations. Furthermore, in vivo brain phosphorus-31 magnetic resonance spectroscopy suggests reduced lipid membrane precursors (phosphomonoesters) and increased membrane breakdown products (phosphodiesters) in drug-naïve or early treated first-episode schizophrenia patients compared to age-matched controls or chronic populations and these changes were correlated with peripheral red blood cell membrane AA levels. We postulate that processes modulating membrane lipid metabolism are associated with psychotic illnesses and might partially explain the mechanism of action of antipsychotic agents, as well as experimental agents such as purified ethyl-eicosapentaenoic acid (E-EPA). Recent supplementation trials suggest that E-EPA is a modestly effective augmentation treatment resulting in reduced doses of antipsychotic medication in acutely ill patients with schizophrenia (but not in residual-type schizophrenia). This review investigates the role of bioactive lipids in schizophrenia and its treatment, as well as its potential use in prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
Feinberg, I. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90038-3 · Cited by 1,395
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., & Levitt, P. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000866 · Cited by 446
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · cited 1×
“Most studies have used EPA as an adjunct to neuroleptic medication with only one small controlled study initially starting acute schizophrenia patients on EPA alone (Peet et al., 2001).”
ResultIncidence of Cancer Among Persons With Schizophrenia and Their Relatives
Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., & Lönnqvist, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.573 · Cited by 292 · cited 1×
“The lower incidence of depression in populations with high intake of marine or sea fish (rich in n-3 fatty acids) provides further support for the importance of life time intake of EFA and proneness to mental illness ( Lichtermann, Ekelund, Pukkala, Tanskanen, & Lonnqvist, 2001; Stoll, 2001; Hibbeln, 1998) although th…”
ResultAt Issue: Schizophrenia and Rheumatoid Arthritis: The Negative Association Revisited
Oken, R. J., & Schulzer, M. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033407 · Cited by 129
Advice to eat fish and mood: a randomised controlled trial in men with angina
Ness, A. R., Gallacher, J. E. J., Bennett, P. D., Gunnell, D. J., Rogers, P. J., Kessler, D., & Burr, M. L. (2003) · Nutritional Neuroscience · doi:10.1080/1028415021000056069 · Cited by 50
Cited by
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Altered Lipid Metabolism in Brain Injury and Disorders
Adibhatla, R. M., & Hatcher, J. F. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_9 · Cited by 401
Biomarkers and clinical staging in psychiatry
McGorry, P., Keshavan, M., Goldstone, S., Amminger, P., Allott, K., Berk, M., Lavoie, S., Pantelis, C., Yung, A., Wood, S., et al. (2014) · World Psychiatry · doi:10.1002/wps.20144 · Cited by 306
Role Of Lipids In Brain Injury And Diseases
Adibhatla, R. M., & Hatcher, J. F. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.403 · Cited by 270
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Metadata
- Authors
- Berger, G. E., Smesny, S., & Amminger, G. P.
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 18
- Issue
- 2
- Pages
- 85-98
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W1976484727
- Cited by
- 79
- References
- 10
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioactive lipids in schizophrenia. https://app.cochat.ai/papers/10.1080/09540260600583072
- The paper
- Berger, G. E., Smesny, S., & Amminger, G. P. (2006). Bioactive lipids in schizophrenia. International Review of Psychiatry. https://doi.org/10.1080/09540260600583072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.